5-Methoxyflavone ameliorates non-alcoholic fatty liver disease through targeting the cytochrome P450 1A1

被引:11
|
作者
Zhang, Yurou [1 ]
Fu, Qinghua [1 ]
Wu, Tian [1 ]
Liu, Kang [1 ]
Xiao, Yang [1 ]
Liao, Qichao [1 ]
Qi, Xinyi [1 ]
Li, Yixing [1 ]
Zhou, Lei [1 ]
机构
[1] Guangxi Univ, Coll Anim Sci & Technol, State Key Lab Conservat & Utilizat Subtrop Agrobio, Nanning 530004, Peoples R China
基金
中国国家自然科学基金;
关键词
5-Methoxyflavone; NAFLD; Oxidative stress; IN-VIVO; FLAVONOIDS; OBESITY; STRESS; GENES; MICE;
D O I
10.1016/j.freeradbiomed.2022.12.093
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent liver disease that is closely related to obesity and metabolic disorders. 5-methoxyflavone (5-MF) is a flavonoid with DNA polymerase-8 inhibitory properties. In this study, we explored the effects of 5-MF on NAFLD and its potential mechanisms using oleic acid/palmitic acid-treated HepG2 cells and high-fat diet-fed C57BL/6J mice. Our results showed that 5-MF not only alleviated fat deposition and hepatic steatosis, but also improved oxidative damage. In addition, 5-MF has the effect of alleviating disorders of glucose metabolism and enhancing energy expenditure in HFD-induced obese mice. Mechanistically, reverse screening methods and molecular docking analysis were used in combination, and revealed that cytochrome P450 1A1 (CYP1A1) is the target for 5-MF. Further experiments showed that 5-MF ameliorated triglycerides deposition by inhibiting the enzyme activity and protein expression of CYP1A1. In conclusion, 5-MF provides a novel strategy for the prevention and treatment of high-fat-induced NAFLD.
引用
收藏
页码:178 / 191
页数:14
相关论文
共 50 条
  • [1] Genistein Ameliorates Non-alcoholic Fatty Liver Disease by Targeting the Thromboxane A2 Pathway
    Wang, Wenzhe
    Chen, Junliang
    Mao, Jinyan
    Li, Hongling
    Wang, Mingfu
    Zhang, Hao
    Li, Haitao
    Chen, Wei
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2018, 66 (23) : 5853 - 5859
  • [2] MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting Yy1
    Ma, Lina
    Song, Huichen
    Zhang, Chen-Yu
    Hou, Dongxia
    BIOMOLECULES, 2024, 14 (01)
  • [3] Regulation of the cytochrome P450 epoxyeicosanoid pathway is associated with distinct histologic features in pediatric non-alcoholic fatty liver disease
    Kalveram, Laura
    Schunck, Wolf-Hagen
    Rothe, Michael
    Rudolph, Birgit
    Loddenkemper, Christoph
    Holzhuetter, Hermann-Georg
    Henning, Stephan
    Bufler, Philip
    Schulz, Marten
    Meierhofer, David
    Zhang, Ingrid W.
    Weylandt, Karsten H.
    Wiegand, Susanna
    Hudert, Christian A.
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2021, 164
  • [4] Hyperoside attenuates non-alcoholic fatty liver disease through targeting Nr4A1 in macrophages
    Sun, Bing
    Zhang, Ranteng
    Liang, Zicong
    Fan, Aoqiang
    Kang, Dongmei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 94
  • [5] Puerarin ameliorates non-alcoholic fatty liver disease by inhibiting lipid metabolism through FMO5
    Li, Zhaoyi
    Cao, Wenjing
    Zhang, Yuxuan
    Lai, Shanglei
    Ye, Yingyan
    Bao, Jianfeng
    Fu, Ai
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [6] Characterization of the Cytochrome P450 epoxyeicosanoid pathway in non-alcoholic steatohepatitis
    Wells, Michael A.
    Vendrov, Kimberly C.
    Edin, Matthew L.
    Ferslew, Brian C.
    Zha, Weibin
    Nguyen, Bobbie K. H.
    Church, Rachel J.
    Lih, Fred B.
    DeGraff, Laura M.
    Brouwer, Kim L. R.
    Barritt, A. Sidney
    Zeldin, Darryl C.
    Lee, Craig R.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2016, 125 : 19 - 29
  • [7] miR-218-5p promotes hepatic lipogenesis through targeting Elovl5 in non-alcoholic fatty liver disease
    Wu, Guanlin
    Zhang, Yan
    Liang, Bo
    Yin, Lianhong
    Gao, Meng
    Zhang, Han
    Xu, Youwei
    Han, Xu
    Qi, Yan
    Liu, Fang
    Xu, Lina
    BIOCHEMICAL PHARMACOLOGY, 2024, 226
  • [8] Cytochrome P450 expression-associated multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) in HepG2 cells
    Sukkasem, Nadta
    Chatuphonprasert, Waranya
    Jarukamjorn, Kanokwan
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (04) : 707 - 714
  • [9] Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
    Miyake, Teruki
    Yoshida, Sakiko
    Furukawa, Shinya
    Sakai, Takenori
    Tada, Fujimasa
    Senba, Hidenori
    Yamamoto, Shin
    Koizumi, Yohei
    Yoshida, Osamu
    Hirooka, Masashi
    Kumagi, Teru
    Niiya, Tetsuju
    Miyaoka, Hiroaki
    Masanori, Abe
    Matsuura, Bunzo
    Hiasa, Yoichi
    OPEN MEDICINE, 2018, 13 (01): : 402 - 409
  • [10] Liver ASK1 protects from non-alcoholic fatty liver disease and fibrosis
    Challa, Tenagne D.
    Wueest, Stephan
    Lucchini, Fabrizio C.
    Dedual, Mara
    Modica, Salvatore
    Borsigova, Marcela
    Wolfrum, Christian
    Blueher, Matthias
    Konrad, Daniel
    EMBO MOLECULAR MEDICINE, 2019, 11 (10)